cardiometabolic

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset

Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……

by Timos Papagatsias

Lucid Diligence Brief - Tech

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic editing to siRNA obesity therapies

Lucid Diligence Brief: Moonwalk Biosciences pivots from CRISPR-based epigenetic…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development

Lucid Diligence Brief: CORXEL $287m Series D1 for oral GLP-1 development…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences

Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences Professional…

by Timos Papagatsias

EASD 2025 Preview: Key Diabetes Highlihts to Watch

EASD 2025 at a glance In the lead-up to EASD 2025, LucidQuest spotlights…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.